English
Home > Products > 307-33-5

China 307-33-5 Factory

In the past few years, our firm absorbed and digested highly developed technologies equally at home and abroad. Meanwhile, our business staffs a group of experts devoted on the growth of 307-33-5,CAS NO 307-33-5,1-chloroheptadecafluorooctane, We warmly welcome all intrigued clients to call us for additional details.
307-33-5, Our staffs are adhering to the "Integrity-based and Interactive Development" spirit, and the tenet of "First-class Quality with Excellent Service". According to the needs of every customer, we provide customized & personalized services to help customers achieve their goals successfully. Welcome clients from home and abroad to call and inquire!

Related Products

Hot Products

  • 2,5-Difluoronitrobenzene

    2,5-Difluoronitrobenzene

    Product Name:2,5-Difluoronitrobenzene
    Molecular Formula:C6H3F2NO2
    Molecular Weight:159.09
    CAS Registry Number:364-74-9
  • Anhydrovinblastine

    Anhydrovinblastine

    Product Name:Anhydrovinblastine
    Molecular Formula:C46H56N4O8
    Molecular Weight:792.96
    CAS Registry Number:38390-45-3
  • Arabinoguanosine

    Arabinoguanosine

    Product Name:Arabinoguanosine
    Molecular Formula:C10H13N5O5
    Molecular Weight:283.24
    CAS Registry Number:38819-10-2
  • Dantrolene sodium

    Dantrolene sodium

    Product Name:Dantrolene sodium
    Molecular Formula:C14H13N4NaO6
    Molecular Weight;356.27
    CAS Registry Number;24868-20-0
  • 9,10-Dibromoanthracene

    9,10-Dibromoanthracene

    Product Name:9,10-Dibromoanthracene
    Molecular Formula:C14H8Br2
    Molecular Weight:336.02
    CAS Registry Number:523-27-3
  • Fluralaner

    Fluralaner

    Product Name:Fluralaner
    Molecular Formula:C22H17Cl2F6N3O3
    Molecular Weight;556.29
    CAS Registry Number;864731-61-3
  • Related Blog
  • Reviews

  • Bosutinib CAS 380843-75-4

    Chemical name:4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications.

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • What are pharmaceutical intermediates?

    Pharmaceutical intermediates are fine chemical products in the production process from pharmaceutical chemical raw materials to bulk drugs or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 307-33-5

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept